David Bosler
Research Subjects
David Bosler has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Abhay Singh
Taussig Cancer Center, Cleveland Clinic
2 shared publications - Ahmed Nabil Mohamed
Department of Internal Medicine, Cleveland Clinic, Cleveland, OH
2 shared publications - Anjali S. Advani
Leukemia Program, Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH
2 shared publications - Emily Craig Zabor
Department of Quantitative Health Sciences Cleveland Clinic Research Cleveland Ohio USA
2 shared publications Joy Nakitandwe
2 shared publications- Moaath Khader Mustafa Ali
Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, USA
2 shared publications
Latest Publications
- Open Access
- 19 June 2026
- Published by Elsevier in SSRN Electronic Journal
The Prognostic Utility of Normal Karyotype Fraction in Acute Myeloid Leukemia
Background: The prognostic significance of the proportion of normal metaphases detected at diagnosis in acute myeloid leukemia (AML) has not been systematically evaluated. Methods: We conducted a retrospective cohort study of 893 adult AML patients treated at Cleveland Clinic between 01/2015-09/2023 who underwent conventional cytogenetic analysis. Normal karyotype fraction (NKF) was defined as the proportion of normal metaphases among all metaphases analyzed at diagnosis. NKF was evaluated as a continuous measure and categorized using three-group (NKF = 0, 0 < NKF < 1, NKF = 1) and five-group functional classification systems. Primary outcomes included overall survival (OS), event-free survival (EFS), composite complete remission (CR/CRi), and relapse. Multivariable Cox proportional hazards and logistic regression models were adjusted for established prognostic covariates. Results: NKF demonstrated a bimodal distribution across the cohort. Patients with NKF = 1 achieved the highest CR/CRi rate (64%) and longest median OS (16 months) and EFS (11 months). In multivariable analyses, NKF = 1 was independently associated with improved OS (HR 0.77, 95%CI 0.61-0.97) and EFS (HR 0.72, 95%CI 0.58-0.90), and higher odds of achieving CR/CRi (OR 1.72, 95%CI 1.10-2.70) compared with NKF = 0. EFS was significantly associated with NKF categories in both classification systems (p <0.05). Conclusion: NKF is a novel, readily obtainable prognostic parameter derived from routine cytogenetics that independently predicts treatment response and survival in AML. External validation and prospective studies are warranted to support its use in clinical risk stratification frameworks.
- 19 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessThe Prognostic Utility of Normal Karyotype Fraction in Acute Myeloid Leukemia
Background: The prognostic significance of the proportion of normal metaphases detected at diagnosis in acute myeloid leukemia (AML) has not been systematically evaluated. Methods: We conducted a retrospective cohort study of 893 adult AML patients treated at Cleveland Clinic between 01/2015-09/2023 who underwent conventional cytogenetic analysis. Normal karyotype fraction (NKF) was defined as the proportion of normal metaphases among all metaphases analyzed at diagnosis. NKF was evaluated as a continuous measure and categorized using three-group (NKF = 0, 0 < NKF < 1, NKF = 1) and five-group functional classification systems. Primary outcomes included overall survival (OS), event-free survival (EFS), composite complete remission (CR/CRi), and relapse. Multivariable Cox proportional hazards and logistic regression models were adjusted for established prognostic covariates. Results: NKF demonstrated a bimodal distribution across the cohort. Patients with NKF = 1 achieved the highest CR/CRi rate (64%) and longest median OS (16 months) and EFS (11 months). In multivariable analyses, NKF = 1 was independently associated with improved OS (HR 0.77, 95%CI 0.61-0.97) and EFS (HR 0.72, 95%CI 0.58-0.90), and higher odds of achieving CR/CRi (OR 1.72, 95%CI 1.10-2.70) compared with NKF = 0. EFS was significantly associated with NKF categories in both classification systems (p <0.05). Conclusion: NKF is a novel, readily obtainable prognostic parameter derived from routine cytogenetics that independently predicts treatment response and survival in AML. External validation and prospective studies are warranted to support its use in clinical risk stratification frameworks.
- 19 May 2025
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 25 (9) , e668-e674.e9
Comparing Outcomes of First-Line Intensive Chemotherapeutic Regimens in Adult Patients With Acute Lymphoblastic Leukemia at a Tertiary Center
- 19 May 2025
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 25 (9) , e668-e674.e9
Comparing Outcomes of First-Line Intensive Chemotherapeutic Regimens in Adult Patients With Acute Lymphoblastic Leukemia at a Tertiary Center
- 2 February 2024
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 26 (4) , 233-244
Engraftment and Measurable Residual Disease Monitoring after Hematopoietic Stem Cell Transplantation
- 2 February 2024
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 26 (4) , 233-244
Engraftment and Measurable Residual Disease Monitoring after Hematopoietic Stem Cell Transplantation
- Open Access
- 31 January 2022
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 24 (5) , 503-514
A Model for Design and Implementation of a Laboratory Information-Management System Specific for Molecular Pathology Laboratory Operations
- 31 January 2022
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 24 (5) , 503-514
Open AccessA Model for Design and Implementation of a Laboratory Information-Management System Specific for Molecular Pathology Laboratory Operations
- 20 October 2021
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 44 (2) , 263-272
A comprehensive analysis of cytopenias and bone marrow morphology in patients with a history of bariatric and metabolic surgery
Introduction Following bariatric and metabolic surgery (BMS), patients may develop persistent cytopenia(s) despite adequate micronutrient levels. A comprehensive analysis of laboratory and hematopathologic findings in BMS patients with unexplained cytopenia(s) has not been previously described. Methods We reviewed the clinical and laboratory data, bone marrow histology, and used ancillary testing to characterize patients with a history of BMS who had subsequent bone marrow biopsies due to unexplained cytopenia(s). Results All patients had anemia and 59% (23/39) had additional cytopenias. Myelodysplastic syndrome (MDS) and clonal cytopenia of unknown significance (CCUS) were diagnosed in 8% (3/39) and 10% (4/39), respectively. Remaining cases were classified as idiopathic cytopenia of unknown significance (ICUS) with anemia alone (ICUS-A) in 47% (15/32) or multiple cytopenias (ICUS-PAN) in 53% (17/32). Time since surgery, age, or amount of weight loss was not associated with a specific diagnosis. No patient was vitamin B12 or folate deficient. However, vitamin B6 and zinc were decreased in 47% (5/11) and 29% (9/29), respectively. Examination of bone marrow aspirates revealed slight erythroid dyspoiesis affecting <10% of precursors in 60% (9/15) ICUS-A and 59% (10/17) ICUS-PAN. Conclusion Bone marrow findings in patients with unexplained cytopenia(s) after BMS are not specific in the majority of cases, and caution is advised when interpreting dyserythropoiesis. Levels of micronutrients and vitamins other than iron, folate and vitamin B12 are frequently disturbed in this patient cohort and warrant correction and close clinical follow-up.
- 20 October 2021
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 44 (2) , 263-272
A comprehensive analysis of cytopenias and bone marrow morphology in patients with a history of bariatric and metabolic surgery
Introduction Following bariatric and metabolic surgery (BMS), patients may develop persistent cytopenia(s) despite adequate micronutrient levels. A comprehensive analysis of laboratory and hematopathologic findings in BMS patients with unexplained cytopenia(s) has not been previously described. Methods We reviewed the clinical and laboratory data, bone marrow histology, and used ancillary testing to characterize patients with a history of BMS who had subsequent bone marrow biopsies due to unexplained cytopenia(s). Results All patients had anemia and 59% (23/39) had additional cytopenias. Myelodysplastic syndrome (MDS) and clonal cytopenia of unknown significance (CCUS) were diagnosed in 8% (3/39) and 10% (4/39), respectively. Remaining cases were classified as idiopathic cytopenia of unknown significance (ICUS) with anemia alone (ICUS-A) in 47% (15/32) or multiple cytopenias (ICUS-PAN) in 53% (17/32). Time since surgery, age, or amount of weight loss was not associated with a specific diagnosis. No patient was vitamin B12 or folate deficient. However, vitamin B6 and zinc were decreased in 47% (5/11) and 29% (9/29), respectively. Examination of bone marrow aspirates revealed slight erythroid dyspoiesis affecting <10% of precursors in 60% (9/15) ICUS-A and 59% (10/17) ICUS-PAN. Conclusion Bone marrow findings in patients with unexplained cytopenia(s) after BMS are not specific in the majority of cases, and caution is advised when interpreting dyserythropoiesis. Levels of micronutrients and vitamins other than iron, folate and vitamin B12 are frequently disturbed in this patient cohort and warrant correction and close clinical follow-up.
- 9 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S55
Anovel TET2 intronic variant leads to alternative splicing in patients with myeloid neoplasm
- 9 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S55
Anovel TET2 intronic variant leads to alternative splicing in patients with myeloid neoplasm
- Open Access
- 1 January 2019
- Published by Elsevier in Cancer Genetics
- Vol. 230, 28-36
Molecular and pathologic characterization of AML with double Inv(3)(q21q26.2)
- 1 January 2019
- Published by Elsevier in Cancer Genetics
- Vol. 230, 28-36
Open AccessMolecular and pathologic characterization of AML with double Inv(3)(q21q26.2)